mefenamic acid

Trade name: ponstel

Small moleculeapproved

Approved

Mar 28, 1967

Mefenamic acid is a non-steroidal anti-inflammatory agent with analgesic, anti-inflammatory, and antipyretic properties. It is used for the treatment of mild to moderate pain, including menstrual pain, inflammation, and fever. Clinical use of mefenamic acid has generally declined in an era where other NSAID use has flourished. While having modes of action and general toxicities similar to other NSAIDs, mefenamic acid, as a member of the fenamates, nevertheless possesses some unique in vitro effects that have the potential to distinguish this agent from others. Use of this drug remains relevant for pain syndromes and some gynecological disorders, albeit with considerable competition from other NSAIDs. New basic science has considerably improved the understanding of the biochemistry of mefenamic acid. As well as maintaining its use in traditional settings, there is a tremendous potential for expanding the application of mefenamic acid to niche roles. Mefenamic acid binds the prostaglandin synthetase receptors COX-1 and COX-2, inhibiting the action of prostaglandin synthetase. Mefenamic acid concentrations reached during therapy have produced in vivo effects. Prostaglandins sensitize afferent nerves and potentiate the action of bradykinin in inducing pain in animal models. Prostaglandins are mediators of inflammation. Because mefenamic acid is an inhibitor of prostaglandin synthesis, its mode of action may be due to a decrease of prostaglandins in peripheral tissues. — NCATS

Clinical trial activity

13 trials · 16 clinical orgs · 12 marketing orgs

Phase 1
5
Phase 2
3
Phase 3
3
Phase 4
2

Earliest trial started Jan 1, 1998 (NCT02183025)

Timeline

1960s

  1. Mar 28, 1967

    Parke-Davis — Earliest FDA Approval

  2. Mar 28, 1967

    Shionogi — NDA Secondary Org

  3. Mar 28, 1967

    Parke-Davis — NDA Organization

  4. Mar 28, 1967

    Avion Pharmaceuticals — Marketing Organization

  5. Mar 28, 1967

    Avion Pharmaceuticals — NDA Secondary Org

1990s

  1. Jan 1, 1998

    Earliest Phase 2 Sponsor(trial)

2010s

  1. Nov 19, 2010

    Micro Labs Ltd India — Marketing Organization

  2. Jul 22, 2011

    Lupin — Marketing Organization

  3. Feb 5, 2013

    Esteve Labs — Marketing Organization

  4. Feb 5, 2013

    Nostrum Laboratories — Marketing Organization

  5. Feb 5, 2013

    MPP PHARMA — Marketing Organization

  6. Jun 2, 2014

    Belcher Pharmaceuticals — Marketing Organization

  7. Jun 2, 2014

    AJENAT PHARMS — Marketing Organization

  8. Jan 1, 2016

    Earliest Phase 3 Sponsor(trial)

  9. Jan 1, 2017

    Earliest Phase 1 Sponsor(trial)

2020s

  1. Sep 18, 2020

    Strides Pharma Science — Marketing Organization

  2. Sep 18, 2020

    Chartwell Pharmaceuticals — Marketing Organization

Indications

Mechanism of action

Approval history

  • approvedMar 28, 1967

Chemistry & pharmacology

Loading structure…

SMILES

CC1=C(C)C(NC2=CC=CC=C2C(O)=O)=CC=C1
Mol. weight
241.2851 g/mol
Lipinski Ro5
Pass
Rule of 3
No
Chirality
Achiral Molecule
Inorganic
No
Polymer
No
Delivery
Oral
Availability
Prescription Only

Oral

Yes

Parenteral

No

Topical

No

Black box warning

Sources

Also known as

  • acide méfénamique
  • acide méfénamique
  • acido mefenamico
  • acido mefenamico
  • acidum mefenamicum
  • acidum mefenamicum
  • ayurved siriraj prasaplai
  • ci-473
  • ci-473
  • cn 35355
  • cn 35355
  • cn-35355
  • cn-35355
  • contraflam
  • contraflam
  • dysman-250
  • dysman-500
  • inf 3355
  • inf 3355
  • inf-3355
  • inf-3355
  • mefananmic acid
  • mefenacid
  • mefenamate
  • mefenamic acid
  • mefenamic acid
  • mefenamic acid
  • mefenamic acid
  • mefenamic acid
  • mefenamic acid
  • mefenamic acid
  • mefenamic acid
  • mefenamic acid
  • mefenamic acid
  • mefenamic acid
  • mefenaminsaeure
  • mefenaminsaeure
  • mefenaminsäure
  • mefenaminsäure
  • meflam 250
  • meflam 500
  • mendys
  • mephenamic acid
  • n-(2,3-xylyl)-2-aminobenzoic acid
  • n-(2,3-xylyl)-2-aminobenzoic acid
  • n-2,3-xylylanthranilic acid
  • n-2,3-xylylanthranilic acid
  • opustan 250
  • opustan 500
  • ponstan
  • ponstan
  • ponstan fte
  • ponstel
  • ponstel
  • ponstel

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT06277609Phase 1Feb 27, 2024Lundbeck
NCT05181007Phase 1Dec 17, 2021Haisco Pharmaceutical
NCT05064449Phase 1Oct 14, 2021Takeda
NCT04902105Phase 1May 13, 2021Emalex Biosciences, Nuventra Pharma Sciences, Inc., Syneos Health
NCT03323671Phase 2/Phase 3 (Phase 3)Aug 1, 2017Mansoura University
NCT03070678Phase 1Mar 14, 2017Sanofi
NCT02943655Phase 3Nov 1, 2016Assiut University
NCT01942122Phase 2/Phase 3 (Phase 3)Oct 1, 2015Dexa Medica Group, University of Indonesia
NCT02417337Phase 2Aug 1, 2012University of Khartoum
NCT01598012Phase 4Dec 1, 2011Mahidol University
NCT01295294Phase 4Mar 1, 2011Bayer
NCT01060696N/AJan 1, 2009Mahidol University, Siriraj Hospital
NCT02183025Phase 2Jan 1, 1998Boehringer Ingelheim
Showing 13 of 13 trials
Page 1 / 1

Organizations

Research & Development (16)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
Mahidol UniversityAcademic/Hospital2222009
Assiut UniversityAcademic/Hospital1112016
BayerFor profit1112011
Boehringer IngelheimFor profit1111998
Dexa Medica GroupFor profit1112015
Emalex BiosciencesFor profit1112021
Haisco PharmaceuticalFor profit1112021
LundbeckFor profit1112024
Mansoura UniversityAcademic/Hospital1112017
Nuventra Pharma Sciences, Inc.For profit1012021
SanofiFor profit1112017
Siriraj HospitalAcademic/Hospital1012009
Syneos HealthFor profit1012021
TakedaFor profit1112021
University of IndonesiaAcademic/Hospital1012015
University of KhartoumAcademic/Hospital1112012
16 organizations
Page 1 / 1

Marketing (15)

OrganizationOrg typeRelationshipDate
AJENAT PHARMSFor profitMKTGJun 2, 2014
Avion PharmaceuticalsFor profitMKTGMar 28, 1967
Avion PharmaceuticalsFor profitNDA2Mar 28, 1967
Belcher PharmaceuticalsFor profitMKTGJun 2, 2014
Belcher PharmaceuticalsFor profitSYNJun 2, 2014
Chartwell PharmaceuticalsFor profitMKTGSep 18, 2020
Esteve LabsFor profitSYNFeb 5, 2013
Esteve LabsFor profitMKTGFeb 5, 2013
LupinFor profitMKTGJul 22, 2011
MPP PHARMAFor profitMKTGFeb 5, 2013
Micro Labs Ltd IndiaFor profitMKTGNov 19, 2010
Nostrum LaboratoriesFor profitMKTGFeb 5, 2013
Parke-DavisFor profitNDAMar 28, 1967
ShionogiFor profitNDA2Mar 28, 1967
Strides Pharma ScienceFor profitMKTGSep 18, 2020